Insmed (NASDAQ:INSM) Cut to “Sell” at Zacks Investment Research
Insmed (NASDAQ:INSM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, January 3rd.
According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
INSM has been the subject of a number of other reports. Leerink Swann boosted their target price on shares of Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, September 5th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Insmed in a research report on Monday, November 6th. Cowen reiterated a “buy” rating and issued a $54.00 price objective on shares of Insmed in a research report on Friday, November 3rd. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $36.67.
Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.69). sell-side analysts anticipate that Insmed will post -2.67 EPS for the current fiscal year.
In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the sale, the director now owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of INSM. BNP Paribas Arbitrage SA grew its stake in shares of Insmed by 666.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 6,520 shares during the period. SG Americas Securities LLC acquired a new position in shares of Insmed in the 2nd quarter worth approximately $129,000. UBS Asset Management Americas Inc. acquired a new position in shares of Insmed in the 2nd quarter worth approximately $187,000. Virtu KCG Holdings LLC acquired a new position in shares of Insmed in the 2nd quarter worth approximately $201,000. Finally, Redmile Group LLC acquired a new position in shares of Insmed in the 2nd quarter worth approximately $212,000. 95.26% of the stock is owned by institutional investors and hedge funds.
WARNING: “Insmed (NASDAQ:INSM) Cut to “Sell” at Zacks Investment Research” was originally published by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.mareainformativa.com/insmed-insm-downgraded-by-zacks-investment-research-to-sell-updated-updated-updated/126699/.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.